出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年6月
ポイントオブケア分子診断市場 : 製品（アッセイ、キット、機器、ソフトウェア）、用途（呼吸器疾患、HAI、がん、STD、肝炎）、テクノロジー（RT-PCR、INAAT）、エンドユーザー（クリニック、病院、ICU） – 2028年までの世界予測
Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Instruments, Software), Application (Respiratory Diseases, HAIs, Cancer, STDs, Hepatitis), Technology (RT-PCR, INAAT), End User (Clinics, Hospitals, ICUs) – Global Forecast to 2028
| ページ数 | 207 |
| 図表数 | 170 |
| 種別 | 英文調査報告書 |
| 価格 |
The global point-of-care molecular diagnostics market size is projected to reach USD 3.4 billion by 2028 from USD 2.0 billion in 2023, at a CAGR of 10.6% during the forecast period. Market growth is driven by factors such as the increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics and increasing R&D funding, increasing awareness on the early detection of infectious diseases, and the increasing use of POC diagnostic tests. On the other hand, stringent and time-consuming regulatory policies that significantly increase the product launch cycle may challenge market growth post their commercialization.
“The assays & kits accounted for the highest growth rate in the point-of-care molecular diagnostics market, by product & service, during the forecast period”
The point-of-care molecular diagnostics market is segmented into assays & kits, instruments & analyzers and software and services. The assays & kits segment accounted for the highest growth rate in the point-of-care molecular diagnostics market in 2022. The requirement assays & kits in large numbers compared to instruments is the main factor contributing to this segment’s high growth rate. This segment’s market growth can also be attributed to repeat purchases of assays & kits compared to instruments.
“Hospitals & ICUs segment accounted for the highest CAGR”
The point-of-care molecular diagnostics market is divided into various end-user segments, including physicians’ offices, hospitals & ICUs, research institutes, and other end users. In 2022, the hospitals & ICUs segment experienced the most significant growth rate. One of the primary advantages of utilizing point-of-care molecular tests in hospitals or clinical settings, as opposed to traditional point-of-care tests, is their ability to provide faster turnaround times and increased accuracy. The hospitals & ICUs segment’s substantial market share can be attributed to the growing number of hospitals and the high demand for diagnostic products within these healthcare facilities.
“Asia Pacific: The fastest-growing region point-of-care molecular diagnostics market”
The global market for point-of-care molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) throughout the forecast period. The remarkable growth in the Asia Pacific market can be attributed to several factors. These include the proactive efforts by governments to raise awareness about early disease detection and promote regular health check-ups, the increasing healthcare expenditure in the region, the rising number of hospitals and clinical diagnostic laboratories in countries like India and China, and the strengthening research capabilities in diagnostic procedures across India, China, and Japan.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18% and Latin America 6% and Middle East & Africa 4%
Prominent companies Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Danaher Corporation (US), QIAGEN N.V. (Netherlands), QuidelOrtho Corporation (US), Co-Diagnostics, Inc. (US), Biocartis NV (Belgium), Meridian Bioscience, Inc. (US), Thermo Fisher Scientific, Inc. (US), Lucira Health, Inc. (US), Cue Health (US), OpGen, Inc. (US), Binx Health, Inc. (US), Molbio Diagnostics Pct. Ltd. (India), Genomadix (Canada), Visby Medical, Inc. (US), QuikPath PTE Ltd. (Singapore), MD-Bio (US), QuantuMDx Group Ltd. (UK), Aidian Oy (Finland), GeneSTAT Molecular Diagnostics, LLC. (US), Labsystems Diagnostics Oy (Finland), Akonni Biosystems (US) and Curetis N.V. (Germany).
Research Coverage:
This research report categorizes the point of care molecular diagnostics market by product & service, technology, application, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the point-of-care molecular diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the point of care molecular diagnostics market. Competitive analysis of upcoming startups in the point of care molecular diagnostics market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall point-of-care molecular diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the point of care molecular diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the point of care molecular diagnostics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the point of care molecular diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the point of care molecular diagnostics market.
• Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Danaher Corporation (US), and QIAGEN N.V. (Netherlands), among others in the point of care molecular diagnostics market strategies.
目次
1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 MARKETS COVERED 29
1.3.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION 29
1.3.2 GEOGRAPHIC SCOPE 30
1.3.3 YEARS CONSIDERED 30
1.4 CURRENCY 31
1.5 STUDY LIMITATIONS 31
1.6 STAKEHOLDERS 31
1.7 SUMMARY OF CHANGES 32
1.7.1 RECESSION IMPACT 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.2 RESEARCH APPROACH 33
FIGURE 1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN 33
2.2.1 SECONDARY DATA 34
2.2.1.1 Key data from secondary sources 34
2.2.2 PRIMARY DATA 35
2.2.2.1 Primary sources 36
2.2.2.2 Key data from primary sources 37
2.2.2.3 Key industry insights 38
2.2.2.4 Breakdown of primary interviews 38
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.3 MARKET SIZE ESTIMATION 39
2.3.1 BOTTOM-UP APPROACH 40
2.3.1.1 Approach 1: Company revenue estimation approach 40
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 40
2.3.1.2 Approach 2: Presentations of companies and primary interviews 40
2.3.1.3 Growth forecast 41
2.3.1.4 CAGR projections 41
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
2.3.2 TOP-DOWN APPROACH 41
FIGURE 6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH 42
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 43
FIGURE 7 DATA TRIANGULATION METHODOLOGY 43
2.5 MARKET SHARE ANALYSIS 43
2.6 STUDY ASSUMPTIONS 44
2.7 LIMITATIONS 44
2.8 RISK ASSESSMENT 45
2.8.1 RISK ASSESSMENT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 45
2.9 RECESSION IMPACT: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 45
3 EXECUTIVE SUMMARY 47
FIGURE 8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 48
FIGURE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 48
FIGURE 11 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 49
FIGURE 12 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 50
4 PREMIUM INSIGHTS 51
4.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW 51
FIGURE 13 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD 51
4.2 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028 51
FIGURE 14 ASSAYS & KITS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028 51
4.3 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2023 VS. 2028 52
FIGURE 15 RT-PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 52
4.4 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2023 VS. 2028 52
FIGURE 16 RESPIRATORY DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 52
4.5 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER, 2023 VS. 2028 53
FIGURE 17 PHYSICIANS’ OFFICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 53
4.6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET DURING FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 19 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.2.1 DRIVERS 55
5.2.1.1 Increasing prevalence of infectious diseases and cancer 55
5.2.1.2 Rising focus on decentralized diagnostics and increasing R&D funding 55
5.2.1.3 Growing awareness of the early detection of infectious diseases 56
5.2.1.4 Increasing use of POC diagnostic tests 57
5.2.2 RESTRAINTS 57
5.2.2.1 Unfavorable reimbursement scenario 57
5.2.2.2 High capital investments and low cost-benefit ratio 58
5.2.3 OPPORTUNITIES 58
5.2.3.1 Growing R&D activities in point-of-care molecular diagnostics testing 58
5.2.3.2 Growth opportunities in emerging economies 58
5.2.4 CHALLENGES 59
5.2.4.1 Stringent and time-consuming regulatory policies that significantly increase product launch cycle 59
5.2.4.2 Introduction of alternative technologies 60
5.3 PRICING ANALYSIS 60
TABLE 1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT 60
5.4 PATENT ANALYSIS 61
FIGURE 20 PATENT ANALYSIS FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS (JANUARY 2013–DECEMBER 2022) 61
5.4.1 LIST OF KEY PATENTS 62
5.5 VALUE CHAIN ANALYSIS 63
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE 63
5.6 SUPPLY CHAIN ANALYSIS 64
FIGURE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS: SUPPLY CHAIN ANALYSIS 65
5.7 ECOSYSTEM ANALYSIS 65
FIGURE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 65
5.7.1 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 66
5.8 PORTER’S FIVE FORCES ANALYSIS 67
TABLE 2 PORTER’S FIVE FORCES ANALYSIS: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 67
5.8.1 THREAT OF NEW ENTRANTS 67
5.8.2 THREAT OF SUBSTITUTES 67
5.8.3 BARGAINING POWER OF SUPPLIERS 67
5.8.4 BARGAINING POWER OF BUYERS 67
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 68
5.9 PESTLE ANALYSIS 68
5.10 REGULATORY ANALYSIS 69
TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 6 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71
5.10.1.1 North America 71
5.10.1.1.1 US 71
5.10.1.1.2 Canada 71
5.10.1.2 Europe 71
5.10.1.3 Asia Pacific 71
5.10.1.3.1 China 71
5.10.1.3.2 Japan 72
5.10.1.3.3 India 72
5.10.1.4 Latin America 72
5.10.1.4.1 Brazil 72
5.10.1.4.2 Mexico 72
5.10.1.5 Middle East 73
5.10.1.6 Africa 73
5.11 TRADE ANALYSIS 73
TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 73
TABLE 9 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 74
5.12 TECHNOLOGY ANALYSIS 74
5.13 KEY CONFERENCES AND EVENTS, 2023–2024 75
TABLE 10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS 75
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 76
FIGURE 24 REVENUE SHIFT IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 76
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 76
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 76
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS 76
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS 77
5.15.2 BUYING CRITERIA 77
FIGURE 26 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTICS PRODUCTS 77
TABLE 12 KEY BUYING CRITERIA FOR POINT-OF-CARE MOLECULAR DIAGNOSTIC PRODUCTS 77
6 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE 78
6.1 INTRODUCTION 79
TABLE 13 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 79
6.2 ASSAYS & KITS 79
6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH 79
TABLE 14 KEY ASSAYS & KITS AVAILABLE IN MARKET 80
TABLE 15 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2021–2028 (USD MILLION) 80
6.3 INSTRUMENTS & ANALYZERS 81
6.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE GROWTH IN MARKET 81
TABLE 16 KEY INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET 81
TABLE 17 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2021–2028 (USD MILLION) 82
6.4 SOFTWARE & SERVICES 82
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND 82
TABLE 18 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET 83
TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION) 83
7 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 84
7.1 INTRODUCTION 85
TABLE 20 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 85
7.2 RT-PCR 85
7.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 85
TABLE 21 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION) 86
7.3 INAAT 86
7.3.1 COST BENEFITS OF INAAT TO BOOST DEMAND 86
TABLE 22 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION) 87
7.4 OTHER TECHNOLOGIES 87
TABLE 23 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION) 87
8 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 88
8.1 INTRODUCTION 89
TABLE 24 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 89
8.2 RESPIRATORY DISEASES 89
8.2.1 RISING DEMAND FOR EARLY DIAGNOSIS AND DETECTION OF RESPIRATORY DISEASES TO DRIVE GROWTH 89
TABLE 25 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2021–2028 (USD MILLION) 90
8.3 SEXUALLY TRANSMITTED DISEASES 90
8.3.1 TECHNOLOGICAL ADVANCEMENTS FOR DETECTION OF STDS TO FAVOR MARKET GROWTH 90
TABLE 26 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2021–2028 (USD MILLION) 91
8.4 HOSPITAL-ACQUIRED INFECTIONS 91
8.4.1 RISING BURDEN OF MRSA TO SUPPORT GROWTH 91
TABLE 27 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2028 (USD MILLION) 92
8.5 CANCER 92
8.5.1 RISING PREVALENCE OF CANCER AND GROWING FUNDING FOR CANCER RESEARCH TO DRIVE MARKET 92
TABLE 28 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 93
8.6 HEPATITIS 93
8.6.1 INCREASING CASES OF HEPATITIS AMONG HIGH-RISK SUBGROUP POPULATIONS TO BOOST GROWTH 93
TABLE 29 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION) 94
8.7 GASTROINTESTINAL DISORDERS 94
8.7.1 GROWING INCIDENCE OF GASTROINTESTINAL DISORDERS TO PROPEL MARKET 94
TABLE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 95
8.8 OTHER APPLICATIONS 95
TABLE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 95
8.9 COVID-19 96
8.9.1 DECLINING CASES OF COVID-19 TO HINDER MARKET GROWTH 96
TABLE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION) 96
9 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER 97
9.1 INTRODUCTION 98
TABLE 33 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 98
9.2 PHYSICIANS’ OFFICES 98
9.2.1 FASTER RESULTS ASSOCIATED WITH POINT-OF-CARE MOLECULAR ASSAYS TO DRIVE GROWTH 98
TABLE 34 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES, BY REGION, 2021–2028 (USD MILLION) 99
9.3 HOSPITALS & ICUS 99
TABLE 35 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 36 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & ICUS, BY DISEASE TYPE, 2021–2028 (USD MILLION) 100
9.3.1 SEPSIS 100
9.3.1.1 Growing need for quick diagnosis and treatment to favor market growth 100
9.3.2 GASTROENTERITIS 101
9.3.2.1 Growing incidence of gastroenteritis cases in emergency departments to propel growth 101
9.3.3 MENINGOENCEPHALITIS 101
9.3.3.1 Severity of disease and need for early detection to drive demand 101
9.3.4 OTHER DISEASES 101
9.4 RESEARCH INSTITUTES 102
9.4.1 INCREASING USE OF POC MOLECULAR DIAGNOSTIC TESTS IN GENOMICS RESEARCH TO CONTRIBUTE TO MARKET GROWTH 102
TABLE 37 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 102
9.5 OTHER END USERS 103
TABLE 38 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 103
10 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION 104
10.1 INTRODUCTION 105
TABLE 39 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 105
10.2 NORTH AMERICA 106
10.2.1 RECESSION IMPACT: NORTH AMERICA 106
FIGURE 27 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 107
TABLE 40 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 41 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 108
TABLE 42 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 108
TABLE 43 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 109
TABLE 44 NORTH AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 109
10.2.2 US 110
10.2.2.1 Growing prevalence of infectious diseases to drive market 110
TABLE 45 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 110
TABLE 46 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 111
TABLE 47 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 48 US: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 112
10.2.3 CANADA 112
10.2.3.1 Rising government initiatives to propel market growth in coming years 112
TABLE 49 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 113
TABLE 50 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 113
TABLE 51 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 113
TABLE 52 CANADA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 114
10.3 EUROPE 114
10.3.1 RECESSION IMPACT: EUROPE 114
TABLE 53 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 54 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 115
TABLE 55 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 115
TABLE 56 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 116
TABLE 57 EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 116
10.3.2 GERMANY 117
10.3.2.1 Increasing healthcare expenditure to drive market growth in Germany 117
TABLE 58 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 117
TABLE 59 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 118
TABLE 60 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 118
TABLE 61 GERMANY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 119
10.3.3 UK 119
10.3.3.1 Increasing prevalence of infectious diseases to fuel growth 119
TABLE 62 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120
TABLE 63 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 120
TABLE 64 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 120
TABLE 65 UK: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10.3.4 FRANCE 121
10.3.4.1 Rising R&D expenditure in France to boost market 121
TABLE 66 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 122
TABLE 67 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 122
TABLE 68 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 69 FRANCE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 123
10.3.5 ITALY 123
10.3.5.1 Adoption of advanced diagnostic technologies to favor growth 123
TABLE 70 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 124
TABLE 71 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 124
TABLE 72 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 73 ITALY: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 125
10.3.6 SPAIN 125
10.3.6.1 Growing demand for genetic testing in Spain to create major growth opportunities for market players 125
TABLE 74 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 125
TABLE 75 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126
TABLE 76 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 77 SPAIN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 127
10.3.7 REST OF EUROPE 127
TABLE 78 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 127
TABLE 79 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128
TABLE 80 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 128
TABLE 81 REST OF EUROPE: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 129
10.4 ASIA PACIFIC 129
10.4.1 RECESSION IMPACT: ASIA PACIFIC 129
FIGURE 28 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 130
TABLE 82 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 83 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 131
TABLE 84 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 131
TABLE 85 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 132
TABLE 86 ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 132
10.4.2 CHINA 133
10.4.2.1 Growing public access to modern healthcare to drive market growth 133
TABLE 87 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 133
TABLE 88 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 134
TABLE 89 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 134
TABLE 90 CHINA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 135
10.4.3 JAPAN 135
10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan 135
TABLE 91 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 136
TABLE 92 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 136
TABLE 93 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 94 JAPAN: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 137
10.4.4 INDIA 137
10.4.4.1 Increasing private & public investments in healthcare system to support market growth 137
TABLE 95 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 138
TABLE 96 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 138
TABLE 97 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138
TABLE 98 INDIA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 139
10.4.5 REST OF ASIA PACIFIC (ROAPAC) 139
TABLE 99 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 140
TABLE 100 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140
TABLE 101 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140
TABLE 102 REST OF ASIA PACIFIC: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 141
10.5 LATIN AMERICA 141
10.5.1 LOW PER CAPITA HEALTH SPENDING TO RESTRAIN MARKET GROWTH 141
10.5.2 RECESSION IMPACT: LATIN AMERICA 142
TABLE 103 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 142
TABLE 104 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 142
TABLE 105 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143
TABLE 106 LATIN AMERICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 143
10.6 MIDDLE EAST & AFRICA 144
10.6.1 LACK OF SKILLED RESOURCES TO RESTRICT MARKET GROWTH 144
10.6.2 RECESSION IMPACT: MIDDLE EAST & AFRICA 144
TABLE 107 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 144
TABLE 108 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 145
TABLE 109 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 145
TABLE 110 MIDDLE EAST & AFRICA: POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 146
11 COMPETITIVE LANDSCAPE 147
11.1 OVERVIEW 147
11.2 STRATEGIES OF KEY PLAYERS 147
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 148
TABLE 111 OVERVIEW OF STRATEGIES DEPLOYED BY KEY POINT-OF-CARE MOLECULAR DIAGNOSTICS MANUFACTURING COMPANIES 148
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 149
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET (2018–2022) 149
11.4 MARKET SHARE ANALYSIS 150
FIGURE 30 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022) 150
TABLE 112 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET SHARE: DEGREE OF COMPETITION 150
11.5 COMPANY EVALUATION QUADRANT 151
11.5.1 LIST OF EVALUATED VENDORS 151
11.5.2 STARS 151
11.5.3 EMERGING LEADERS 151
11.5.4 PERVASIVE PLAYERS 151
11.5.5 PARTICIPANTS 152
FIGURE 31 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2022 152
11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2022) 153
11.6.1 PROGRESSIVE COMPANIES 153
11.6.2 STARTING BLOCKS 153
11.6.3 RESPONSIVE COMPANIES 153
11.6.4 DYNAMIC COMPANIES 153
FIGURE 32 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2022 154
11.7 COMPETITIVE BENCHMARKING 155
11.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS 155
FIGURE 33 PRODUCT & SERVICE AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET 155
TABLE 113 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY REGIONAL FOOTPRINT 155
TABLE 114 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT 155
TABLE 115 POINT-OF-CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 156
11.8 COMPETITIVE SCENARIO 157
11.8.1 PRODUCT LAUNCHES & APPROVALS 157
TABLE 116 KEY PRODUCT LAUNCHES & APPROVALS 157
11.8.2 DEALS 158
TABLE 117 KEY DEALS 158
12 COMPANY PROFILES 159
12.1 KEY PLAYERS 159
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABBOTT LABORATORIES 159
TABLE 118 ABBOTT LABORATORIES: BUSINESS OVERVIEW 159
FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 160
12.1.2 F. HOFFMANN-LA ROCHE LTD. 163
TABLE 119 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 163
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 164
12.1.3 BIOMÉRIEUX SA 167
TABLE 120 BIOMÉRIEUX SA: BUSINESS OVERVIEW 167
FIGURE 36 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2022) 168
12.1.4 DANAHER CORPORATION 171
TABLE 121 DANAHER CORPORATION: BUSINESS OVERVIEW 171
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 172
12.1.5 QIAGEN N.V. 175
TABLE 122 QIAGEN N.V.: BUSINESS OVERVIEW 175
FIGURE 38 QIAGEN N.V.: COMPANY SNAPSHOT (2022) 176
12.1.6 QUIDELORTHO CORPORATION 179
TABLE 123 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW 179
FIGURE 39 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 180
12.1.7 CO-DIAGNOSTICS, INC. 182
TABLE 124 CO-DIAGNOSTICS INC.: BUSINESS OVERVIEW 182
FIGURE 40 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022) 182
12.1.8 BIOCARTIS NV 185
TABLE 125 BIOCARTIS NV: BUSINESS OVERVIEW 185
FIGURE 41 BIOCARTIS NV: COMPANY SNAPSHOT (2022) 186
12.1.9 MERIDIAN BIOSCIENCE, INC. 189
TABLE 126 MERIDIAN BIOSCIENCE, INC.: BUSINESS OVERVIEW 189
FIGURE 42 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2022) 190
12.1.10 THERMO FISHER SCIENTIFIC INC. 193
TABLE 127 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 193
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 194
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 196
12.2.1 LUCIRA HEALTH, INC. 196
12.2.2 CUE HEALTH 197
12.2.3 OPGEN, INC. 197
12.2.4 BINX HEALTH, INC. 198
12.2.5 MOLBIO DIAGNOSTICS PVT. LTD. 198
12.2.6 GENOMADIX 200
12.2.7 VISBY MEDICAL, INC. 200
12.2.8 QUIKPATH PTE. LTD. 201
12.2.9 MD-BIO 201
12.2.10 QUANTUMDX GROUP LTD. 201
12.2.11 AIDIAN OY 202
12.2.12 GENESTAT MOLECULAR DIAGNOSTICS, LLC. 202
12.2.13 LABSYSTEMS DIAGNOSTICS OY 203
12.2.14 AKONNI BIOSYSTEMS 203
12.2.15 CURETIS N.V. 204
13 APPENDIX 205
13.1 DISCUSSION GUIDE 205
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 209
13.3 AVAILABLE CUSTOMIZATIONS 211
13.4 RELATED REPORTS 211
13.5 AUTHOR DETAILS 212